Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Genitourinary 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 60Neoplasms 7Gastro-enteropancreatic neuroendocrine tumor 7Carcinoid Tumor 6Breast Neoplasms 6Pheochromocytoma 5Colorectal Neoplasms 5Carcinoma, Renal Cell 5Adenoma, Islet Cell 5Urinary Bladder Neoplasms 4Thyroid Neoplasms 4Paraganglioma 4Neoplasm Metastasis 4Lung Neoplasms 4Carcinoma, Neuroendocrine 4Carcinoma, Hepatocellular 4Brain Neoplasms 4Small Cell Lung Carcinoma 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Melanoma 3Carcinoma, Medullary 3Adrenocortical Carcinoma 3Uveal Melanoma 2Uterine Cervical Neoplasms 2Testicular Neoplasms 2Sarcoma 2Neuroectodermal Tumors, Primitive 2Lymphoma 2Liver Neoplasms 2

Interventions

exemestane 1Injections 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Tuberous Sclerosis × NET × Clear all
NCT07369505 2026-01-27

Sapu003 in Advanced mTOR-sensitive Solid Tumors

SAPU NANO (US) LLC

Phase 1 Recruiting
27 enrolled
EndocrineGastrointestinalGenitourinaryNET

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Tuberous Sclerosis, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡